We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 59

Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


Proactive pharma patent enforcement on Canadian drug combos
  • Bereskin & Parr LLP
  • Canada
  • May 14 2015

The Canadian Patented Medicine (Notice of Compliance) Regulations ("NOC Regulations") allow a patent owner to apply to Federal Court to keep a


The Supreme Court refuses to grant leave to hear “promise of the patent” appeals
  • Bereskin & Parr LLP
  • Canada
  • April 27 2015

On April 23, 2015, the Supreme Court of Canada denied leave to hear an appeal from the Federal Court of Appeal decision in Apotex Inc v Pfizer Canada


Biosimilar battlegrounds - what is new in biosimilars and where?
  • Bereskin & Parr LLP
  • Canada, European Union, USA
  • February 17 2012

Biosimilars are second entry biologic drugs


Expert opinion as to what “one would expect” is speculation, not evidence
  • Bereskin & Parr LLP
  • Canada
  • March 4 2015

In the latest of a trilogy of cases under the Patented Medicines (Notice of Compliance) Regulations relating to the drug tadalafil (CIALIS), Justice


CIPO updates guidance on medical use claims
  • Bereskin & Parr LLP
  • Canada
  • March 23 2015

On March 18, 2015 the Canadian Intellectual Property Office issued a practice notice containing revised examination practice guidelines pertaining to


Good news for the biotech industry patent eligibility of Myriad isolated DNA and methods of screening claims confirmed after Supreme Court’s Mayo ruling
  • Bereskin & Parr LLP
  • Canada
  • August 20 2012

On August 16, 2012, the U.S. Federal Circuit Court of Appeals issued its judgment in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Myriad) partly overturning the district court’s summary judgment that Myriad’s claims were drawn to patent ineligible subject matter and affirmed Myriad’s right to patent isolated DNA of BRCA1 and BRCA2, two genes linked to breast and ovarian cancer


Licensing basics for life sciences: getting paid through license fees
  • Bereskin & Parr LLP
  • Canada
  • February 28 2013

In life sciences, licensing fees are often upfront payments, ongoing royalties (usually a percentage of net sales) or milestone payments after a


Federal court considers “functionally” - limited claims in a biologic case
  • Bereskin & Parr LLP
  • Canada
  • January 22 2014

The Federal Court of Canada recently issued a decision in AbbVie Corporation v. Janssen Inc.,2014 FC 55, involving infringement and validity of a


Biosimilar monoclonal antibodies emerge from the pipeline on both sides of the Atlantic
  • Bereskin & Parr LLP
  • Canada, European Union
  • March 7 2014

The European Medicines Agency ("EMEA") made its biosimilar monoclonal antibody guidelines effective in December 20121. Less than a year later, in